[1. Patel MR, Conte MS, Cutlip DE, et al. Evaluation and treatment of patients with lower extremity peripheral artery disease: consensus definitions from Peripheral Academic Research Consortium (PARC). J Am Coll Cardiol. 2015;65:931-941. doi: 10.1016/j.jacc.2014.12.036.10.1016/j.jacc.2014.12.036]Open DOISearch in Google Scholar
[2. Dua A, Lee CJ. Epidemiology of Peripheral Arterial Disease and Critical Limb Ischemia. Tech Vasc Interv Radiol. 2016;19:91-95. doi: 10.1053/j.tvir.2016.04.001.10.1053/j.tvir.2016.04.001]Open DOISearch in Google Scholar
[3. Eraso LH, Fukaya E, Mohler ER III., Xie D, Sha D, Berger JS. Peripheral arterial disease, prevalence and cumulative risk factor profile analysis. Eur J Prev Cardiol. 2014;21:704-711. doi:10.1177/2047487312452968.10.1177/2047487312452968]Open DOISearch in Google Scholar
[4. Fowkes F, Rudan D, Rudan I, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013;382:1329-1340. doi: http://dx.doi.org/10.1016/S0140-6736(13)61249-0.10.1016/S0140-6736(13)61249-0]Open DOISearch in Google Scholar
[5. Varu VN, Hogg ME, Kibbe MR. Critical limb ischemia. J Vasc Surg. 2010;51:230-241. doi: 10.1016/j.jvs.2009.08.073.10.1016/j.jvs.2009.08.073]Open DOISearch in Google Scholar
[6. Abu Dabrh AM, Steffen MW, Undavalli C, et al. The natural history of untreated severe or critical limb ischemia. J Vasc Surg. 2015;62:1642-1651. doi: 10.1016/j.jvs.2015.07.065.10.1016/j.jvs.2015.07.065]Open DOISearch in Google Scholar
[7. Becker F, Robert-Ebadi H, Ricco JB, et al. Chapter I: definitions, epidemiology, clinical presentation and prognosis. Eur J Vasc Endovasc Surg. 2011;42:S4-S12. doi: 10.1016/S1078-5884(11)60009-9.10.1016/S1078-5884(11)60009-9]Search in Google Scholar
[8. Shishehbor MH, White CJ, Gray BH, Menard MT, Lookstein R, Jaff MR. Critical Limb Ischemia: An Expert Statement. J Am Coll Cardiol. 2016;68:2002-2015. doi:10.1016/j.jacc.2016.04.071.10.1016/j.jacc.2016.04.07127692726]Search in Google Scholar
[9. Dattilo PB, Casserly IP. Critical limb ischemia: endovascular strategies for limb salvage. Prog Cardiovasc Dis. 2011;54:47-60. doi: 10.1016/j.pcad.2011.02.009.10.1016/j.pcad.2011.02.00921722787]Open DOISearch in Google Scholar
[10. Mandolfino T, Canciglia A, Lamberto S, Calogero S, D'Alfonso M, Bottari A. Extreme endovascular revascularization for limb salvage in critical limb ischemia. Int Angiol. 2012;31:163-168.]Search in Google Scholar
[11. Callum K, Bradbury A. Acute limb ischaemia. BMJ : British Medical Journal. 2000;320:764-767.10.1136/bmj.320.7237.764111776910720362]Search in Google Scholar
[12. Beyersdorf F, Schlensak C. Controlled reperfusion after acute and persistent limb ischemia. Semin Vasc Surg. 2009;22:52-57. doi: 10.1053/j.semvascsurg.2009.01.005.10.1053/j.semvascsurg.2009.01.005]Open DOISearch in Google Scholar
[13. Gilliland C, Shah J, Martin JG, Miller MJ Jr. Acute Limb Ischemia. Tech Vasc Interv Radiol. 2017;20:274-280. doi: 10.1053/j.tvir.2017.10.008.10.1053/j.tvir.2017.10.008]Open DOISearch in Google Scholar
[14. Compagna R, Amato B, Massa S, et al. Cell Therapy in Patients with Critical Limb Ischemia. Stem Cells Int. 2015;2015:931420. doi: 10.1155/2015/931420.10.1155/2015/931420]Search in Google Scholar
[15. Simons JP, Goodney PP, Nolan BW, et al. Failure to achieve clinical improvement despite graft patency in patients undergoing infrainguinal lower extremity bypass for critical limb ischemia. J Vasc Surg. 2010;51:1419-1424. doi: 10.1016/j.jvs.2010.01.083.10.1016/j.jvs.2010.01.083]Open DOISearch in Google Scholar
[16. Lawall H, Bramlage P, Amann B. Stem cell and progenitor cell therapy in peripheral artery disease. A critical appraisal. Thromb Haemost. 2010;103:696-709. doi: 10.1160/TH09-10-0688.10.1160/TH09-10-0688]Open DOISearch in Google Scholar
[17. Adam DJ, Beard JD, Cleveland T, Bell J, Bradbury AW, Forbes JF. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet. 2005;366:1925-1934. doi: 10.1016/S0140-6736(05)67704-5.10.1016/S0140-6736(05)67704-5]Open DOISearch in Google Scholar
[18. Fowkes FG, Murray GD, Butcher I, et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA. 2008;300:197-208. doi: 10.1001/jama.300.2.197.10.1001/jama.300.2.197293262818612117]Open DOISearch in Google Scholar
[19. Kum S, Tan YK, Schreve MA, et al. Midterm Outcomes From a Pilot Study of Percutaneous Deep Vein Arterialization for the Treatment of No-Option Critical Limb Ischemia. J Endovasc Ther. 2017;24:619-626. doi: 10.1177/1526602817719283.10.1177/152660281771928328697694]Open DOISearch in Google Scholar
[20. Chen XP, Fu WM, Gu W. Spinal Cord stimulation for patients with inoperable chronic critical leg ischemia. World J Emerg Med. 2011;2:262-266. doi: 10.5847/wjem.j.1920-8642.2011.04.003.10.5847/wjem.j.1920-8642.2011.04.003412971925215020]Open DOISearch in Google Scholar
[21. Walker C. Pedal access in critical limb ischemia. J Cardiovasc Surg (Torino). 2014;55:225-227.10.1007/978-1-4614-7312-1_65]Search in Google Scholar
[22. Tawfick WA, Hamada N, Soylu E, Fahy A, Hynes N, Sultan S. Sequential compression biomechanical device versus primary amputation in patients with critical limb ischemia. Vasc Endovascular Surg. 2013;47:532-539. doi: 10.1177/1538574413499413.10.1177/153857441349941324052447]Open DOISearch in Google Scholar
[23. Qadura M, Terenzi DC, Verma S, Al-Omran M, Hess DA. Cell Therapy for Critical Limb Ischemia: An Integrated Review of Pre-clinical and Clinical Studies. Stem Cells. 2017; doi: 10.1002/stem.2751. [Epub ahead of print]10.1002/stem.2751.[Epubaheadprint]Open DOISearch in Google Scholar
[24. Pignon B, Sevestre MA, Kanagaratnam L, et al. Autologous Bone Marrow Mononuclear Cell Implantation and Its Impact on the Outcome of Patients With Critical Limb Ischemia – Results of a Randomized, Double-Blind, Placebo-Controlled Trial. Circ J. 2017;81:1713-1720. doi: 10.1253/circj.CJ-17-0045.10.1253/circj.CJ-17-0045]Open DOISearch in Google Scholar
[25. Ismail AM, Abdou SM, Aty HA, et al. Autologous transplantation of CD34(+) bone marrow derived mononuclear cells in management of non-reconstructable critical lower limb ischemia. Cytotechnology. 2016;68:771-781. doi: 10.1007/s10616-014-9828-7.10.1007/s10616-014-9828-7]Open DOISearch in Google Scholar
[26. Perotti C, Arici V, Cervio M, et al. Allogeneic lethally irradiated cord blood mononuclear cells in no-option critical limb ischemia: a “box of rain”. Stem Cells Dev. 2013;22:2806-2812. doi: 10.1089/scd.2013.0172.10.1089/scd.2013.0172]Open DOISearch in Google Scholar
[27. Liew A, O'Brien T. Therapeutic potential for mesenchymal stem cell transplantation in critical limb ischemia. Stem Cell Res Ther. 2012;3:28. doi: 10.1186/scrt119.10.1186/scrt119]Open DOISearch in Google Scholar
[28. Koshikawa M, Shimodaira S, Yoshioka T, et al. Therapeutic angiogenesis by bone marrow implantation for critical hand ischemia in patients with peripheral arterial disease: a pilot study. Curr Med Res Opin. 2006;22:793-798. doi: 10.1185/030079906X1000078.10.1185/030079906X1000078]Open DOISearch in Google Scholar
[29. Hernández P1, Cortina L, Artaza H, et al. Autologous bone-marrow mononuclear cell implantation in patients with severe lower limb ischaemia: a comparison of using blood cell separator and Ficoll density gradient centrifugation. Atherosclerosis. 2007;194:e52-56. doi: 10.1016/j.atherosclerosis.2006.08.025.10.1016/j.atherosclerosis.2006.08.025]Open DOISearch in Google Scholar
[30. Lachmann N, Nikol S. Therapeutic angiogenesis for peripheral artery disease: stem cell therapy. Vasa. 2007;36:241-251. doi:10.1024/0301-1526.36.4.241.10.1024/0301-1526.36.4.241]Open DOISearch in Google Scholar
[31. Napoli C, Farzati B, Sica V, et al. Beneficial effects of autologous bone marrow cell infusion and antioxidants/L-arginine in patients with chronic critical limb ischemia. Eur J Cardiovasc Prev Rehabil. 2008;15:709-718. doi: 10.1097/HJR.0b013e3283193a0f.10.1097/HJR.0b013e3283193a0f]Open DOISearch in Google Scholar
[32. Risau W. Mechanisms of angiogenesis. Nature. 1997;386:671-674. doi: 10.1038/386671a0.10.1038/386671a0]Open DOISearch in Google Scholar
[33. Ouma GO, Zafrir B, Mohler ER 3rd, Flugelman MY. Therapeutic angiogenesis in critical limb ischemia. Angiology. 2013;64:466-480. doi: 10.1177/0003319712464514.10.1177/0003319712464514]Open DOISearch in Google Scholar
[34. Annex BH. Therapeutic angiogenesis for critical limb ischaemia. Nat Rev Cardiol. 2013;10:387-396. doi: 10.1038/nrcardio.2013.70.23670612]Search in Google Scholar
[35. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med. 2000;6:389-395.10.1038/74651]Open DOISearch in Google Scholar
[36. Davies MG. Criticial Limb Ischemia: Epidemiology. Methodist DeBakey Cardiovascular Journal. 2012;8:10-14.10.14797/mdcj-8-4-10]Search in Google Scholar
[37. Ribatti D, Vacca A, Nico B, Presta M, Roncali L. Angiogenesis: basic and clinical aspects. Ital J Anat Embryol. 2003;108:1-24.]Search in Google Scholar
[38. Semenza GL. Vasculogenesis, angiogenesis, and arteriogenesis: mechanisms of blood vessel formation and remodeling. J Cell Biochem. 2007;102:840-847. doi: 10.1002/jcb.21523.10.1002/jcb.21523]Open DOISearch in Google Scholar
[39. Axnick J, Lammert E. Vascular lumen formation. Curr Opin Hematol. 2012;19:192-198. doi: 10.1097/MOH.0b013e3283523ebc.10.1097/MOH.0b013e3283523ebc]Open DOISearch in Google Scholar
[40. Zhu S, Liu X, Li Y, Goldschmidt-Clermont PJ, Dong C. Aging in the atherosclerosis milieu may accelerate the consumption of bone marrow endothelial progenitor cells. Arterioscler Thromb Vasc Biol. 2007;27:113-119. doi: 10.1161/01.ATV.0000252035.12881.d0.10.1161/01.ATV.0000252035.12881.d0]Open DOISearch in Google Scholar
[41. van Royen N, Piek JJ, Buschmann I, Hoefer I, Voskuil M, Schaper W. Stimulation of arteriogenesis; a new concept for the treatment of arterial occlusive disease. Cardiovasc Res. 2001;49:543-553.10.1016/S0008-6363(00)00206-6]Search in Google Scholar
[42. Helisch A, Schaper W. Arteriogenesis: the development and growth of collateral arteries. Microcirculation. 2003;10:83-97. doi: 10.1038/sj.mn.7800173.10.1038/sj.mn.780017312610665]Search in Google Scholar
[43. Cai W, Schaper W. Mechanisms of arteriogenesis. Acta Biochim Biophys Sin (Shanghai). 2008;40:681-92.10.1093/abbs/40.8.681]Search in Google Scholar
[44. Fung E, Helisch A. Macrophages in Collateral Arteriogenesis. Frontiers in Physiology. 2012;3:353. doi:10.3389/fphys.2012.00353.10.3389/fphys.2012.00353]Open DOISearch in Google Scholar
[45. Jaipersad AS, Lip GY, Silverman S, Shantsila E. The role of monocytes in angiogenesis and atherosclerosis. J Am Coll Cardiol. 2014;63:1-11. doi: 10.1016/j.jacc.2013.09.019.10.1016/j.jacc.2013.09.019]Open DOISearch in Google Scholar
[46. Sanada F, Taniyama Y, Azuma J, et al. Therapeutic Angiogenesis by Gene Therapy for Critical Limb Ischemia: Choice of Biological Agent. Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry. 2014;14:32-39. doi: 10.2174/1871522213999131231105139.10.2174/1871522213999131231105139]Open DOISearch in Google Scholar
[47. Liew A, Bhattacharya V, Shaw J, Stansby G. Cell Therapy for Critical Limb Ischemia: A Meta-Analysis of Randomized Controlled Trials. Angiology. 2016;67:444-455. doi: 10.1177/0003319715595172.10.1177/0003319715595172]Open DOISearch in Google Scholar
[48. Tongers J, Roncalli JG, Losordo DW. Therapeutic angiogenesis for critical limb ischemia: microvascular therapies coming of age. Circulation. 2008;118:9-16. doi: 10.1161/CIRCULATIONAHA.108.784371.10.1161/CIRCULATIONAHA.108.784371]Open DOISearch in Google Scholar
[49. Cross MJ, Claesson-Welsh L. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci. 2001;22:201-207.10.1016/S0165-6147(00)01676-X]Search in Google Scholar
[50. Ho TK, Rajkumar V, Ponticos M, et al. Increased endogenous angiogenic response and hypoxia-inducible factor-1alpha in human critical limb ischemia. J Vasc Surg. 2006;43:125-133. doi: 10.1016/j.jvs.2005.08.042.10.1016/j.jvs.2005.08.042]Open DOISearch in Google Scholar
[51. Henning RJ. Therapeutic angiogenesis: angiogenic growth factors for ischemic heart disease. Future Cardiol. 2016;12:585-599. doi: 10.2217/fca-2016-0006.10.2217/fca-2016-0006]Open DOISearch in Google Scholar
[52. Tille JC, Wood J, Mandriota SJ, et al. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF-and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro. J Pharmacol Exp Ther. 2001;299:1073-1085.]Search in Google Scholar
[53. Kim SK, Lee J, Song M, et al. Combination of three angiogenic growth factors has synergistic effects on sprouting of endothelial cell/mesenchymal stem cell-based spheroids in a 3D matrix. J Biomed Mater Res B Appl Biomater. 2016;104:1535-1543. doi: 10.1002/jbm.b.33498.10.1002/jbm.b.33498]Open DOISearch in Google Scholar
[54. Lederman RJ, Mendelsohn FO, Anderson RD, et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet. 2002;359:2053-2058.10.1016/S0140-6736(02)08937-7]Search in Google Scholar
[55. Rajagopalan S, Mohler E 3rd, Lederman RJ, et al. Regional Angiogenesis with Vascular Endothelial Growth Factor (VEGF) in peripheral arterial disease: Design of the RAVE trial. Am Heart J. 2003;145:1114-1118. doi: 10.1016/S0002-8703(03)00102-9.10.1016/S0002-8703(03)00102-9]Open DOISearch in Google Scholar
[56. Nikol S, Baumgartner I, Van Belle E, et al. Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Mol Ther. 2008;16:972-978. doi: 10.1038/mt.2008.33.10.1038/mt.2008.3318388929]Open DOISearch in Google Scholar
[57. Creager MA, Olin JW, Belch JJ, et al. Effect of hypoxia-inducible factor-1alpha gene therapy on walking performance in patients with intermittent claudication. Circulation. 2011;124:1765-1773. doi: 10.1161/CIRCULATIONAHA.110.009407.10.1161/CIRCULATIONAHA.110.00940721947297]Open DOISearch in Google Scholar
[58. Gu Y, Zhang J, Guo L, Cui S, Li X, Ding D, et al. A phase I clinical study of naked DNA expressing two isoforms of hepatocyte growth factor to treat patients with critical limb ischemia. J Gene Med. 2011;13:602-610. doi: 10.1002/jgm.1614.10.1002/jgm.161422015632]Open DOISearch in Google Scholar
[59. Conte MS, Bandyk DF, Clowes AW, et al. Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. J Vasc Surg. 2006;43:742-751. doi: 10.1016/j.jvs.2005.12.058.10.1016/j.jvs.2005.12.05816616230]Open DOISearch in Google Scholar
[60. Comerota AJ, Throm RC, Miller KA, et al. Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a phase I trial. J Vasc Surg. 2002;35:930-936.10.1067/mva.2002.12367712021709]Open DOISearch in Google Scholar
[61. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;275:964-967.10.1126/science.275.5302.9649020076]Search in Google Scholar
[62. Gupta R, Losordo DW. Cell Therapy for Critical Limb Ischemia Moving Forward One Step at a Time. Circ Cardiovasc Interv. 2011;4:2-5. doi: 10.1161/CIRCINTERVENTIONS.110.960716.10.1161/CIRCINTERVENTIONS.110.960716312377821325196]Open DOISearch in Google Scholar
[63. Nizankowski R, Petriczek T, Skotnicki A, Szczeklik A. The treatment of advanced chronic lower limb ischaemia with marrow stem cell autotransplantation. Kardiol Pol. 2005;63:351-360.]Search in Google Scholar
[64. Tanaka M, Taketomi K, Yonemitsu Y. Therapeutic angiogenesis: recent and future prospects of gene therapy in peripheral artery disease. Curr Gene Ther. 2014;14:300-308.10.2174/15665232140414090212483825197884]Open DOISearch in Google Scholar
[65. Procházka V, Gumulec J, Chmelová J, et al. Autologous bone marrow stem cell transplantation in patients with end-stage chronical critical limb ischemia and diabetic foot. Vnitr Lek. 2009;55:173-178.]Search in Google Scholar
[66. Brewster L, Robinson S, Wang R, et al. Expansion and angiogenic potential of mesenchymal stem cells from patients with critical limb ischemia. J Vasc Surg. 2017;65:826-838. doi: 10.1016/j.jvs.2015.02.061.10.1016/j.jvs.2015.02.061499677726921003]Open DOISearch in Google Scholar
[67. Kawamura A, Horie T, Tsuda I, et al. Clinical study of therapeutic angiogenesis by autologous peripheral blood stem cell (PBSC) transplantation in 92 patients with critically ischemic limbs. J Artif Organs. 2006;9:226-233. doi: 10.1007/s10047-006-0351-2.10.1007/s10047-006-0351-217171401]Open DOISearch in Google Scholar
[68. Huang PP, Yang XF, Li SZ, Wen JC, Zhang Y, Han ZC. Randomised comparison of G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow-mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans. Thromb Haemost. 2007;98:1335-1342.10.1160/TH07-02-013718064333]Search in Google Scholar
[69. Botti C, Maione C, Coppola A, Sica V, Cobellis G. Autologous bone marrow cell therapy for peripheral arterial disease. Stem Cells and Cloning: Advances and Applications. 2012;5:5-14. doi:10.2147/SCCAA.S28121.10.2147/SCCAA.S28121378176124198534]Open DOISearch in Google Scholar
[70. Motukuru V, Suresh KR, Vivekanand V, Raj S, Girija KR. Therapeutic angiogenesis in Buerger's disease (thromboangiitis obliterans) patients with critical limb ischemia by autologous transplantation of bone marrow mononuclear cells. J Vasc Surg. 2008;48:53S-60S. doi: 10.1016/j.jvs.2008.09.005.10.1016/j.jvs.2008.09.00519084740]Open DOISearch in Google Scholar
[71. Ruiz-Salmeron R, de la Cuesta-Diaz A, Constantino-Bermejo M, et al. Angiographic demonstration of neoangiogenesis after intra-arterial infusion of autologous bone marrow mononuclear cells in diabetic patients with critical limb ischemia. Cell Transplant. 2011;20:1629-1639. doi: 10.3727/096368910X0177.10.3727/096368910X017722289660]Open DOISearch in Google Scholar
[72. Huang P, Li S, Han M, Xiao Z, Yang R, Han ZC. Autologous transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes. Diabetes Care. 2005;28:2155-2160.10.2337/diacare.28.9.215516123483]Open DOISearch in Google Scholar
[73. Lara-Hernandez R, Lozano-Vilardell P, Blanes P, Torreguitart-Mirada N, Galmés A, Besalduch J. Safety and efficacy of therapeutic angiogenesis as a novel treatment in patients with critical limb ischemia. Ann Vasc Surg. 2010;24:287-294. doi: 10.1016/j.avsg.2009.10.012.10.1016/j.avsg.2009.10.01220142004]Open DOISearch in Google Scholar
[74. Burt RK, Testori A, Oyama Y, et al. Autologous peripheral blood CD133+ cell implantation for limb salvage in patients with critical limb ischemia. Bone Marrow Transplant. 2010;45:111-116. doi: 10.1038/bmt.2009.102.10.1038/bmt.2009.102395186019448678]Open DOISearch in Google Scholar
[75. Losordo DW, Kibbe MR, Mendelsohn F, et al. A Randomized, Controlled Pilot Study of Autologous CD34+ Cell Therapy for Critical Limb Ischemia. Circulation Cardiovascular interventions. 2012;5:821-830. doi:10.1161/CIRCINTERVENTIONS.112.968321.10.1161/CIRCINTERVENTIONS.112.968321354939723192920]Open DOISearch in Google Scholar
[76. Dash NR, Dash SN, Routray P, Mohapatra S, Mohapatra PC. Targeting nonhealing ulcers of lower extremity in human through autologous bone marrow-derived mesenchymal stem cells. Rejuvenation Res. 2009;12:359-366. doi: 10.1089/rej.2009.0872.10.1089/rej.2009.087219929258]Open DOISearch in Google Scholar
[77. Yan J, Tie G, Xu TY, Cecchini K, Messina LM. Mesenchymal stem cells as a treatment for peripheral arterial disease: current status and potential impact of type II diabetes on their therapeutic efficacy. Stem Cell Rev. 2013;9:360-372. doi: 10.1007/s12015-013-9433-8.10.1007/s12015-013-9433-8]Open DOISearch in Google Scholar
[78. Bura A, Planat-Benard V, Bourin P, et al. Phase I trial: the use of autologous cultured adipose-derived stroma/stem cells to treat patients with non-revascularizable critical limb ischemia. Cytotherapy. 2014;16:245-257. doi: 10.1016/j.jcyt.2013.11.011.10.1016/j.jcyt.2013.11.011]Open DOISearch in Google Scholar
[79. Das AK, Bin Abdullah BJ, Dhillon SS, Vijanari A, Anoop CH, Gupta PK. Intra-arterial allogeneic mesenchymal stem cells for critical limb ischemia are safe and efficacious: report of a phase I study. World J Surg. 2013;37:915-922. doi: 10.1007/s00268-012-1892-6.10.1007/s00268-012-1892-6]Open DOISearch in Google Scholar
[80. Gyöngyösi M, Hemetsberger R, Wolbank S, et al. Delayed recovery of myocardial blood flow after intracoronary stem cell administration. Stem Cell Rev. 2011;7:616-623. doi: 10.1007/s12015-010-9213-7.10.1007/s12015-010-9213-7]Open DOISearch in Google Scholar
[81. Gyöngyösi M, Wojakowski W, Lemarchand P, et al. Meta-Analysis of Cell-based CaRdiac stUdiEs (ACCRUE) in patients with acute myocardial infarction based on individual patient data. Circ Res. 2015;116:1346-1360. doi: 10.1161/CIRCRESAHA.116.304346.10.1161/CIRCRESAHA.116.304346]Open DOISearch in Google Scholar
[82. Moazzami K, Majdzadeh R, Nedjat S. Local intramuscular transplantation of autologous mononuclear cells for critical lower limb ischaemia. Cochrane Database Syst Rev. 2011;12:CD008347. doi: 10.1002/14651858.CD008347.pub2.10.1002/14651858.CD008347.pub2]Open DOISearch in Google Scholar
[83. Takagi G, Miyamoto M, Tara S, et al. Therapeutic vascular angiogenesis for intractable macroangiopathy-related digital ulcer in patients with systemic sclerosis: a pilot study. Rheumatology (Oxford). 2014;53:854-859. doi: 10.1093/rheumatology/ket432.10.1093/rheumatology/ket432]Open DOISearch in Google Scholar
[84. Amato B, Compagna R, Della Corte GA, et al. Peripheral blood mono-nuclear cells implantation in patients with peripheral arterial disease: a pilot study for clinical and biochemical outcome of neoangiogenesis. BMC Surgery. 2012;12:S1. doi:10.1186/1471-2482-12-S1-S1.10.1186/1471-2482-12-S1-S1]Open DOISearch in Google Scholar
[85. Maksimov AV, Kiiasov AP, Plotnikov MV, et al. Outcomes of using autologous peripheral-blood stem cells in patients with chronic lower arterial insufficiency. Angiol Sosud Khir. 2011;17:11-15.]Search in Google Scholar
[86. Tateishi-Yuyama E, Matsubara H, Murohara T, et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet. 2002;360:427-435. doi: 10.1016/S0140-6736(02)09670-8.10.1016/S0140-6736(02)09670-8]Open DOISearch in Google Scholar
[87. Procházka V, Gumulec J, Jalůvka F, et al. Cell therapy, a new standard in management of chronic critical limb ischemia and foot ulcer. Cell Transplant. 2010;19:1413-1424. doi: 10.3727/096368910X514170.10.3727/096368910X514170547838220529449]Open DOISearch in Google Scholar
[88. Walter DH, Krankenberg H, Balzer JO, et al. Intraarterial administration of bone marrow mononuclear cells in patients with critical limb ischemia: a randomized-start, placebo-controlled pilot trial (PROVASA). Circ Cardiovasc Interv. 2011;4:26-37. doi: 10.1161/CIRCINTERVENTIONS.110.958348.10.1161/CIRCINTERVENTIONS.110.95834821205939]Open DOISearch in Google Scholar
[89. Cobellis G, Silvestroni A, Lillo S, et al. Long-term effects of repeated autologous transplantation of bone marrow cells in patients affected by peripheral arterial disease. Bone Marrow Transplant. 2008;42:667-672. doi: 10.1038/bmt.2008.228.10.1038/bmt.2008.22818695661]Open DOISearch in Google Scholar
[90. Van Tongeren RB, Hamming JF, Fibbe WE, et al. Intramuscular or combined intramuscular/intra-arterial administration of bone marrow mononuclear cells: a clinical trial in patients with advanced limb ischemia. J Cardiovasc Surg (Torino). 2008;49:51-58.]Search in Google Scholar
[91. Matoba S, Tatsumi T, Murohara T, et al. Long-term clinical outcome after intramuscular implantation of bone marrow mononuclear cells (Therapeutic Angiogenesis by Cell Transplantation [TACT] trial) in patients with chronic limb ischemia. Am Heart J. 2008;156:1010-1018. doi: 10.1016/j.ahj.2008.06.025.10.1016/j.ahj.2008.06.02519061721]Open DOISearch in Google Scholar
[92. Amann B, Luedemann C, Ratei R, Schmidt-Lucke JA. Autologous bone marrow cell transplantation increases leg perfusion and reduces amputations in patients with advanced critical limb ischemia due to peripheral artery disease. Cell Transplant. 2009;18:371-380.10.3727/09636890978853494219500466]Open DOISearch in Google Scholar
[93. Lawall H, Bramlage P, Amann B. Treatment of peripheral arterial disease using stem and progenitor cell therapy. J Vasc Surg. 2011;53:445-453. doi: 10.1016/j.jvs.2010.08.060.10.1016/j.jvs.2010.08.06021030198]Open DOISearch in Google Scholar
[94. Dhong Z, Chen B, Fu W, et al. Transplantation of purified CD34+ cells in the treatment of critical limb ischemia. Journal of Vascular Surgery. 2013;58:404-411. doi: http://dx.doi.org/10.1016/j.jvs.2013.01.037.10.1016/j.jvs.2013.01.03723611711]Open DOISearch in Google Scholar
[95. Rigato M, Monami M, Fadini GP. Autologous Cell Therapy for Peripheral Arterial Disease: Systematic Review and Meta-Analysis of Randomized, Nonrandomized, and Noncontrolled Studies. Circ Res. 2017;120:1326-1340. doi: 10.1161/CIRCRESAHA.116.309045.10.1161/CIRCRESAHA.116.30904528096194]Open DOISearch in Google Scholar
[96. Idei N, Soga J, Hata T, et al. Autologous bone-marrow mononuclear cell implantation reduces long-term major amputation risk in patients with critical limb ischemia: a comparison of atherosclerotic peripheral arterial disease and Buerger disease. Circ Cardiovasc Interv. 2011;4:15-25. doi: 10.1161/CIRCINTERVENTIONS.110.955724.10.1161/CIRCINTERVENTIONS.110.95572421205941]Open DOISearch in Google Scholar
[97. Heeschen C, Lehmann R, Honold J, et al. Profoundly reduced neovascularization capacity of bone marrow mononuclear cells derived from patients with chronic ischemic heart disease. Circulation. 2004;109:1615-1622. doi: 10.1161/01.CIR.0000124476.32871.E3.10.1161/01.CIR.0000124476.32871.E315037527]Open DOISearch in Google Scholar
[98. Li TS, Kubo M, Ueda K, et al. Identification of risk factors related to poor angiogenic potency of bone marrow cells from different patients. Circulation. 2009;120:S255-261. doi: 10.1161/CIRCULATIONAHA.108.837039.10.1161/CIRCULATIONAHA.108.83703919752376]Open DOISearch in Google Scholar
[99. Gyöngyösi M, Hemetsberger R, Posa A, et al. Hypoxiainducible factor 1-alpha release after intracoronary versus intramyocardial stem cell therapy in myocardial infarction. J Cardiovasc Transl Res. 2010;3:114-121. doi: 10.1007/s12265-009-9154-1.10.1007/s12265-009-9154-120560024]Open DOISearch in Google Scholar
[100. Gremmels H, Teraa M, Quax PH, den Ouden K, Fledderus JO, Verhaar MC. Neovascularization capacity of mesenchymal stromal cells from critical limb ischemia patients is equivalent to healthy controls. Mol Ther. 2014;22:1960-1970. doi: 10.1038/mt.2014.161.10.1038/mt.2014.161442973825174586]Open DOISearch in Google Scholar
[101. Benedek I, Bucur O, Benedek T. Intracoronary infusion of mononuclear bone marrow-derived stem cells is associated with a lower plaque burden after four years. J Atheroscler Thromb. 2014;21:217-229.10.5551/jat.1974524126180]Open DOISearch in Google Scholar
[102. Madaric J, Klepanec A, Valachovicova M, et al. Characteristics of responders to autologous bone marrow cell therapy for no-option critical limb ischemia. Stem Cell Res Ther. 2016;7:116. doi: 10.1186/s13287-016-0379-z.10.1186/s13287-016-0379-z498796827530339]Open DOISearch in Google Scholar
[103. Powell RJ, Marston WA, Berceli SA, et al. Cellular therapy with Ixmyelocel-T to treat critical limb ischemia: the randomized, double-blind, placebo-controlled RESTORE-CLI trial. Mol Ther. 2012;20:1280-1286. doi: 10.1038/mt.2012.52.10.1038/mt.2012.52336929122453769]Open DOISearch in Google Scholar
[104. Jadlowiec C, Brenes RA, Li X, et al. Stem cell therapy for critical limb ischemia: what can we learn from cell therapy for chronic wounds? Vascular. 2012;20:284-289. doi: 10.1258/vasc.2011.201206.10.1258/vasc.2011.201206367565023086986]Open DOISearch in Google Scholar